Hypertensive myocardial fibrosis adversely affects cardiac function, coronary reserve, and electrical activity, highlighting the need for noninvasive monitoring and targeted therapies.
Development of noninvasive tools for monitoring myocardial fibrosis and pharmacological strategies to promote its regression are relevant for treating hypertensive heart disease.
Myocardial fibrosis is one of the histologic constituents of myocardial remodeling present in hypertensive patients with hypertensive heart disease. In fact, an exaggerated interstitial and perivascular accumulation of fibrillar collagens type I and type III has been found in the myocardium of patients with arterial hypertension and left ventricular hypertrophy. Hypertensive myocardial fibrosis has been shown to facilitate abnormalities of cardiac function, coronary reserve, and electrical activity that adversely affect the clinical outcome of hypertensive patients. Therefore, development of noninvasive tools for the monitoring of myocardial fibrosis and pharmacological strategies aimed to promote the regression of fibrosis could be of particular relevance in the clinical treatment of patients with hypertensive heart disease.
Dı́ez et al. (Thu,) conducted a review in Hypertensive myocardial fibrosis. Hypertensive myocardial fibrosis adversely affects cardiac function, coronary reserve, and electrical activity, highlighting the need for noninvasive monitoring and targeted therapies.